A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 135
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : TDI
Long Form : Transition Dyspnea Index
No. Year Title Co-occurring Abbreviation
2020 Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADO and OTEMTO Studies. CI, COPD, FEV1, GOLD, LABA, LAMA, OR, OTEMTO, SGRQ
2020 COPD Maintenance Therapy with Tiotropium/Olodaterol Compared with Tiotropium: An Analysis in the Absence of Additional ICS Therapy. CI, FEV1, GOLD, ICS, LABA, LAMA, SGRQ
2020 Design of the Redefining Therapy in Early COPD Study. BDI, CAT, FEF25-75, FEV1, FVC, RETHINC, SGRQ
2020 Effect of Zephyr Endobronchial Valves on Dyspnea, Activity Levels, and Quality of Life at One Year. Results from a Randomized Clinical Trial. CAT, EXACT, PROs, SGRQ
2020 Efficacy and Safety of Once-Daily Inhaled Umeclidinium in Asian Patients with COPD: Results from a Randomized, Placebo-Controlled Study. AEs, CFB, CI, COPD, FEV1, LS, UMEC
2020 Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis. COPD, FEV1, GOLD, ITT, SGRQ
2020 Efficacy of Tiotropium/Olodaterol Compared with Tiotropium as a First-Line Maintenance Treatment in Patients with COPD Who Are Naive to LAMA, LABA and ICS: Pooled Analysis of Four Clinical Trials. CI, COPD, FEV1, ICS, LABAs, LAMAs, RCT, SGRQ
2020 First-Line Treatment with Tiotropium/Olodaterol Improves Physical Activity in Patients with Treatment-Naive Chronic Obstructive Pulmonary Disease. 6MWD, BMI, CAT, COPD, METs
2020 Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long-acting bronchodilator-naive COPD patients: A pooled analysis. COPD, eDiary, FEV1, IND/GLY, LABD, LAMA, OL, SGRQ, TIO
10  2020 Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study. BDI, CAT, COPD, FF, HRQoL, SGRQ, UMEC
11  2020 Symptom Improvement Following Treatment with the Inhaled Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine in Patients with Moderate to Severe COPD - A Detailed Analysis. COPD, PDE, SGRQ-C
12  2020 Treatment With Mycophenolate and Cyclophosphamide Leads to Clinically Meaningful Improvements in Patient-Reported Outcomes in Scleroderma Lung Disease: Results of Scleroderma Lung Study II. CYC, FVC, MCID, MMF, PROs, SGRQ, SSc-ILD
13  2019 Effect of smoking status on lung function, patient-reported outcomes, and safety among COPD patients treated with glycopyrrolate inhalation powder: pooled analysis of GEM1 and GEM2 studies. AEs, CAT, FEV1, ICS, PROs, SAEs, SGRQ
14  2019 Effects of baseline symptom burden on treatment response in COPD. mMRC, SGRQ
15  2019 Efficacy and safety of glycopyrrolate in patients with COPD by reversibility: pooled analysis of GEM1 and GEM2 12-week studies. GLY, SGRQ
16  2019 Efficacy of aclidinium/formoterol 400/12 g, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT. EXACT, HCRU
17  2019 Healthcare Professionals' Preferred Efficacy Endpoints and Minimal Clinically Important Differences in the Assessment of New Medicines for Chronic Obstructive Pulmonary Disease. COPD, FEV1, MCIDs, SGRQ
18  2019 Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis. COPD, FDCs, FEV1, ICS, LAMA, RCTs, SGRQ, SUCRA
19  2019 Real-life effectiveness of indacaterol-glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: the POWER study. CAT, FDC, ICS, IND/GLY, LABA, OD, RCTs, SFC
20  2019 Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting beta2-agonist fixed-dose combinations in COPD. AUC, COPD, FDC, FEV1, LABA, LAMA, NMA, SGRQ
21  2019 The Impact of Twice-Daily Indacaterol/Glycopyrrolate on the Components of Health-Related Quality of Life and Dyspnea in Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease. COPD, HRQoL, IND/GLY, SGRQ
22  2019 Treatment response in COPD: does FEV1 say it all? A post hoc analysis of the CRYSTAL study. CAT, CCQ, COPD, FEV1, PROs
23  2019 Videogame assisted exercise training in patients with chronic obstructive pulmonary disease: A preliminary study. BODE, COPD, MRC, SGRQ
24  2018 Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD). CAGR, COPD, FDA, FDC, ICS, LABA, LAMA, MCID, NNTB, RCTs, SAEs, SGRQ, WHO
25  2018 Correlations between FEV1 and patient-reported outcomes: A pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease. COPD, PROs, SGRQ
26  2018 Early Changes in eDiary COPD Symptoms Predict Clinically Relevant Treatment Response at 12Weeks: Analysis from the CRYSTAL Study. COPD, eDiary, FEV1, GLY, IND/GLY
27  2018 Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: The FLASH randomized controlled trial. CAT, COPD, FEV1, FVC, ICS, IND/GLY, OD, SFC
28  2018 Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study. CCQ, CID, FEV1, LABA, LAMA, OR
29  2018 LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review. ET, FDCs, FEV1, IC, ICS, LABA, LAMA, SGRQ
30  2018 Once-Daily Triple Therapy in Patients with COPD: Patient-Reported Symptoms and Quality of Life. BUD/FOR, CAT, COPD, E-RS, HRQoL, SGRQ
31  2018 Tiotropium plus formoterol versus tiotropium alone for stable moderate-to-severe chronic obstructive pulmonary disease: Ameta-analysis. CI, MD, OR, RCTs
32  2017 A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting beta2-Agonist (LABA) Combinations in COPD. COPD, FEV1, LABA, LAMA, NMA, RCTs, SGRQ, TIO
33  2017 Assessment of the efficacy and safety of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler versus a multi-dose inhaler in patients with chronic obstructive pulmonary disease. CI, COPD, FEV1, LS
34  2017 Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial. COPD, FDC, FEV1, GOLD, ICS, LABA, LAMA
35  2017 Efficacy and safety of indacaterol in patients with chronic obstructive pulmonary disease aged over 65 years: A pooled analysis. COPD, FEV1, SGRQ
36  2017 Efficacy and safety of indacaterol/glycopyrronium fixed-dose combination in mild-to-moderate COPD patients symptomatic on tiotropium in Korea: study protocol for a randomized controlled trial. CAT, COPD, FEV1, IND/GLY, LABA, LAMA
37  2017 Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis. CI, LABA, LAMA, OLO, RCT, RR, SGRQ, TIO
38  2017 High-pressure versus low-pressure home non-invasive positive pressure ventilation with built-in software in patients with stable hypercapnic COPD: a pilot study. IPAP, NPPV
39  2017 Long-acting beta2-agonists versus long-acting muscarinic antagonists in patients with stable COPD: A systematic review and meta-analysis of randomized controlled trials. COPD, FEV1, LABA, LAMA, SGRQ
40  2017 Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol. AB, BID, COPD, FEV1, FF, HR, SGRQ
41  2017 Rescue medication use as a patient-reported outcome in COPD: a systematic review and regression analysis. CFB, COPD, SGRQ
42  2017 Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD). CAGR, CI, COPD, GSK, MD, NNTB, OR, RCTs, SGRQ, WHO
43  2017 Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study. AEs, CAT, CI, FEV1, LS, mMRC, SGRQ, TIO, UMEC
44  2017 Validity of a Self-administered Questionnaire Version of the Transition Dyspnea Index in Patients with COPD. COPD, mMRC, PR
45  2016 Can roflumilast, a phosphodiesterase-4 inhibitor, improve clinical outcomes in patients with moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis. CI, COPD, FVC, MD, RevMan, RR, SGRQ
46  2016 Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting beta2-agonists: a systematic review and network meta-analysis. COPD, FDCs, LABA, LAMA, NMA, RCTs, SGRQ, tFEV1
47  2016 Dual Bronchodilator Therapy with Umeclidinium/Vilanterol Versus Tiotropium plus Indacaterol in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial. AEs, CI, COPD, FEV1, LS, SGRQ, TIO, UMEC/VI, WM
48  2016 Effects of Adding Tiotropium or Aclidinium as Triple Therapy Using Impulse Oscillometry in COPD. ACL, ICS/LABA, IOS, SGRQ, TIO
49  2016 Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO studies. COPD, FEV1, GOLD, ICS, SGRQ
50  2016 Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study. COPD, FEV1, SGRQ
51  2016 Efficacy and Safety of Aclidinium/Formoterol versus Tiotropium in COPD: Results of an Indirect Treatment Comparison. AE, COPD, CrI, DCFB, FEV1, HRQoL, ITC, OR, SAE, SGRQ
52  2016 Efficacy and Safety of an Aclidinium Bromide Treatment for 12 Weeks or Longer in Patients with Moderate-To-Severe COPD: A Meta-Analysis. CI, COPD, MD, OR, RCTs, SGRQ
53  2016 Efficacy and safety of long-acting beta-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis. CrI, LABA/LAMA, SGRQ
54  2016 Efficacy and Safety of Twice-Daily Glycopyrrolate Versus Placebo in Patients With COPD: The GEM2 Study. AUC, FEV1, SGRQ
55  2016 Efficacy of Indacaterol/Glycopyrronium in Patients with COPD Who Have Increased Dyspnea with Daily Activities. BDI, COPD, FEV1, GOLD, IND/GLY, LABA, LAMA, OR, SFC
56  2016 Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis. FVC, GOLD, IND/GLY, SFC
57  2016 Long-acting Muscarinic Antagonist Versus Inhaled Corticosteroid when Added to Long-acting beta-agonist for COPD: A Meta-analysis. CAT, COPD, FEV1, ICS, LABA/LAMA, MD, SGRQ
58  2016 Relationship Between FEV1 and Patient-Reported Outcomes Changes: Results of a Meta-Analysis of Randomized Trials in Stable COPD. AUC, CFB, CI, COPD, FEV1, PRO, SGRQ
59  2016 Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. BDP/FF, COPD, FEV1
60  2016 The effect of umeclidinium added to inhaled corticosteroid/long-acting beta2-agonist in patients with symptomatic COPD: a randomised, double-blind, parallel-group study. AEs, CAT, FEV1, ICS, LABA, LAMA, PBO, UMEC, WM
61  2016 [LAMA/LABA fixed dose combination for treatment of COPD]. FEV1, SGRQ
62  2015 A meta-analysis of four randomized clinical trials to confirm the reliability and responsiveness of the Shortness of Breath with Daily Activities (SOBDA) questionnaire in chronic obstructive pulmonary disease. BDI, CAT, COPD, FEV1, mMRC, PRO, SGRQ, SOBDA
63  2015 Comparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysis. FEV1, NMA, SGRQ, TIO, UMEC/VI
64  2015 Development of a Composite Outcome Measure for Systemic Sclerosis Related Interstitial Lung Disease. CYC, FVC, HAQ-DI, HRCT, PCA, QLF-ZM, SLS I, SSc-ILD
65  2015 Efficacy and safety of aclidinium bromide in patients with COPD: A phase 3 randomized clinical trial in a Korean population. COPD, SGRQ
66  2015 Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled study. CI, FEV1, UMEC, WM
67  2015 Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study. FEV1, FVC, HRQoL, OD, SGRQ-C
68  2015 Is Blood Eosinophil Count a Predictor of Response to Bronchodilators in Chronic Obstructive Pulmonary Disease? Results from Post Hoc Subgroup Analyses. AE, COPD, EOS, ICSs, SGRQ, UMEC
69  2015 Long-acting muscarinic antagonist + long-acting beta agonist versus long-acting beta agonist + inhaled corticosteroid for COPD: A systematic review and meta-analysis. COPD, FEV1, LAMA, OR, SGRQ
70  2015 QVA149 Improves Lung Function, Dyspnea, and Health Status Independent of Previously Prescribed Medications and COPD Severity: A Subgroup Analysis from the SHINE and ILLUMINATE Studies. LABA, LAMA, SGRQ
71  2015 The impact of treatment with indacaterol in patients with COPD: A post-hoc analysis according to GOLD 2011 categories A to D. COPD, FEV1, GOLD, mMRC, SGRQ
72  2014 Dyspnoea related to pre-excitation during sinus rhythm as a new indication for catheter ablation. BDI, CPET, RFA, WPW
73  2014 Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. COPD, FDC, FEV1
74  2014 Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study. AUC30min-4h, COPD, FEV1, FVC, GLY, IND
75  2014 Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. COPD, FDC, SGRQ
76  2014 Extrafine beclomethasone/formoterol compared to fluticasone/salmeterol combination therapy in COPD. BDP/FF, FP/S
77  2014 Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: a pooled analysis of four clinical trials. COPD
78  2013 ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients. COPD, SGRQ
79  2013 Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis. CFB, COPD, FEV1, LAMA, NMA, OD, RCTs, SGRQ
80  2013 Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis. COPD, CrI, FEV1, OD, SGRQ
81  2013 Does roflumilast improve dyspnea in patients with chronic obstructive pulmonary disease? A meta-analysis. CIs, COPD, MCID, RCTs, Rof, SOBQ, WMDs
82  2013 Efficacy and safety of indacaterol and tiotropium in COPD patients according todyspnoea severity. COPD, FEV1, mMRC, SGRQ
83  2013 Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25mcg inCOPD. AEs, COPD, SGRQ, SOBDA, UMEC/VI
84  2013 Noninvasive positive pressure ventilation in subjects with stable COPD: a randomized trial. COPD, CRQ, NPPV
85  2013 Safety and efficacy of the once-daily anticholinergic BEA2180 compared with tiotropium in patients with COPD. COPD, FEV1, SGRQ
86  2012 Assessing efficacy of indacaterol in moderate and severe COPD patients: a 12-week study in an Asian population. LSMs, MCID, SGRQ
87  2012 Comparison of indacaterol with tiotropium or twice-daily long-acting beta -agonists for stable COPD: a systematic review. MCID, NNTB
88  2012 Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). AEs, COPD, SGRQ
89  2012 Efficacy of indacaterol 75 mug once-daily on dyspnea and health status: results of two double-blind, placebo-controlled 12-week studies. MCID, SGRQ
90  2012 Longitudinal changes in patient-reported dyspnea in patients with COPD. COPD, mMRC, PBD, PRD, SAC, UCSD SOBQ
91  2011 Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. COPD, SGRQ
92  2011 Comparative efficacy of indacaterol 150 mug and 300 mug versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease--a network meta-analysis. CFB, COPD, FDC, FOR/BUD, RCTs, SGRQ
93  2011 Comparison of tiotropium plus formoterol to tiotropium alone in stable chronic obstructive pulmonary disease: a meta-analysis. CI, OR, WMD
94  2011 Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis. COPD, SGRQ
95  2011 Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study. AUC
96  2011 Measures of systemic sclerosis (scleroderma): Health Assessment Questionnaire (HAQ) and Scleroderma HAQ (SHAQ), physician- and patient-rated global assessments, Symptom Burden Index (SBI), University of California, Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Scale (UCLA SCTC GIT) 2.0, Baseline Dyspnea Index (BDI) and Transition Dyspnea Index (TDI) (Mahler's Index), Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR), and Raynaud's Condition Score (RCS). BDI, CAMPHOR, HAQ, RCS, SBI, SHAQ
97  2011 Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD. MCID, SGRQ
98  2010 A randomized pilot study of acupuncture as an adjunct therapy in adult asthmatic patients. IgE, PEF, QLQAKA
99  2010 Effect of tiotropium on quality of life in COPD: a systematic review. COPD, MCID, QOL, SGRQ
100  2010 Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies. SMI